Teva

CompanyUnited States

Teva develops 2 assets, the furthest in phase 3 (TVB-009P in postmenopausal osteoporosis). Mostly antibody and small molecule acting on TNFSF11, SNCA and proteostasis; based in the United States.

Assets
2
Furthest
Phase 3
Trials
36
Signals
0

Pipeline

2

  • TVB-009P

    Monoclonal antibody inhibiting RANKL to reduce bone resorption

    Phase 3AntibodyTNFSF11postmenopausal osteoporosis

  • emrusolmin

    Inhibits alpha-synuclein aggregation and misfolding.

    Phase 2Small moleculeSNCAProteostasismultiple system atrophy

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms3
  • Trials44
  • Signals1
  • Similar companies6

Updated 7 Oct 2026 · 31 sources

Intelligence